Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In- / 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. - Juweid,M.E.; Stadtmauer,E.; Hajjar,G.; Sharkey,R.M.; Suleiman,S.; Luger,S.; Swayne,L.C.; Alavi,A.; Goldenberg,D.M. (Clin Cancer Res, 1999)